ED
NRIX icon

Exane Derivatives’s Nurix Therapeutics NRIX Stock Holding History

Exane Derivatives’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,300
Closed -$71.5K – 1071
2021
Q1 		$71.5K Buy
+2,300
New +$87K 0.02% 475

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Exane Derivatives's NRIX Position: Q2 2021 in Review

Exane Derivatives sold out of Nurix Therapeutics (NRIX) in Q2 2021, closing a stake of 2,300 shares — an estimated $71.5K sold.

Exane Derivatives first reported a position in NRIX in Q1 2021 and held it in 1 quarter. The position peaked at $71.5K in Q1 2021. 103 funds tracked by Wall St. Rank hold NRIX as of Q2 2021.

  • Exane Derivatives reported no remaining Nurix Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Exane Derivatives sold 2,300 Nurix Therapeutics shares in Q2 2021, an estimated $71.5K.
  • Exane Derivatives first reported a position in Nurix Therapeutics in Q1 2021 and held it in 1 quarter.
  • Exane Derivatives's Nurix Therapeutics position peaked at $71.5K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.